Skip to main content

Ovarian cancer

Ovarian cancer is the deadliest of gynecological malignancies. Despite repeatedly demonstrated association of immune infiltration and survival, immunotherapy with check point blockade has had modest effect in ovarian cancer due to a highly heterogeneous immune response and lack of sensitive companion diagnostics. Instead, most patients receive standard therapy; surgery and platinum-based chemotherapy, after which 75% recur within 3 years typically with incurable cancer. We apply spatial omics to generate prognostic prediction models and an increased pathobiological understanding of the heterogeneity of immune responses in relation to ovarian cancer subtypes, which will be pivotal for the design of personalized treatment strategies.

 

Page Manager: jana.hagman@immun.lth.se | 2021-08-19